FinnCap restated their corporate rating on shares of Avacta Group (LON:AVCT) in a research note released on Monday morning. FinnCap currently has a GBX 200 ($2.71) price objective on the biotechnology company’s stock.
Shares of Avacta Group (AVCT) opened at GBX 67 ($0.91) on Monday. Avacta Group has a 1-year low of GBX 60 ($0.81) and a 1-year high of GBX 98 ($1.33). The stock has a market capitalization of $36.43 and a P/E ratio of -744.44.
WARNING: “Avacta Group (AVCT) Earns Corporate Rating from FinnCap” was first reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this article on another website, it was copied illegally and reposted in violation of international copyright legislation. The original version of this article can be read at https://ledgergazette.com/2018/01/18/avacta-group-avct-earns-corporate-rating-from-finncap.html.
Avacta Group Company Profile
Avacta Group plc is a biotechnology company. Avacta’s focus is on its proprietary Affimer technology which is an engineered alternative to antibodies that has application in Life Sciences for diagnostics, therapeutics and general research and development. Affimer technology has been designed to address performance limitations of antibodies.
Receive News & Ratings for Avacta Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avacta Group and related companies with MarketBeat.com's FREE daily email newsletter.